Move Your Drug to Market, Faster
As an oncology CRO (contract research organization) dedicated to precision medicine, Translational Drug Development (TD2) works with innovative biotech and pharma companies to bring cancer treatments to patients as quickly as possible.
Support for Every Research Milestone
Our clients have exclusive access to an integrated suite of tools that support every research milestone, and efficiently—from preclinical process to regulatory strategy, clinical support and an expansive patient database that makes recruiting easier than ever.
- Preclinical: Fast-track your research with an integrative and diverse suite of preclinical tools, from more than 300 tumor models that align with a well-defined clinical and regulatory strategy (in vivo, in vitro, and specialized tumor models) to bioanalytical and ADME support.
- Bioanalytical: Launch your efficacy experiments the right way with real-time analysis—from in vivo and in vitro assays to leading-edge equipment in mass spectrometry, modeling platforms and more.
- Regulatory: Clear compliance hurdles to move your drug from the lab to the clinic, and quickly. We’ll manage the IND submission paperwork, filing, pre-IND meetings and everything else along your path to FDA approval.
- Clinical: Get faster results through diligent planning and unmatched clinical experience, and fill enrollment more quickly with a searchable database of millions of trial-ready cancer patients.
Minimize Risk During Drug Development
Protect your project against risk with advanced scientific tools built around tumor models, combination strategies and mutational context identification to give your new agents the greatest chance of success. After all, the future of oncology drug discovery depends on accurately defining the clinical research strategy that will give your drug an advantage in the clinic and then and aligning that strategy with clinical execution.
An Impact on Modern-Day Oncology
Born from the Translational Genomics Research Institute (TGen), TD2 was formed in 2003 as a subsidiary of TGen, and less than two years later, opened its doors on the campus of the Mayo Clinic in Scottsdale, Ariz. In our 15 years of business, we have helped more than 600 biotech and pharma companies, maintaining hundreds of client studies per year. Among them, our team has been involved in more than 600 first-in-man major oncology medicines, including numerous trials that have led to approvals in both rare and large indications.
Ask us how you can get your oncology drug to the market faster with TD2.